Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Apr 21.
Published in final edited form as: Immunity. 2015 Apr 21;42(4):679–691. doi: 10.1016/j.immuni.2015.03.013

Methyl-CpG binding protein 2 regulates microglia and macrophage gene expression in response to inflammatory stimuli

James C Cronk 1,2,3,4,*, Noël C Derecki 1,2,3,*, Emily Ji 1,2, Yang Xu 8, Aaron E Lampano 8, Igor Smirnov 1,2, Wendy Baker 1,2, Geoffrey T Norris 1,2,3, Ioana Marin 1,2,3, Nathan Coddington 1,2, Yochai Wolf 9, Stephen D Turner 6, Alan Aderem 10, Alexander L Klibanov 5,7, Tajie H Harris 1,2,3, Steffen Jung 9, Vladimir Litvak 8,#, Jonathan Kipnis 1,2,3,4,#
PMCID: PMC4407145  NIHMSID: NIHMS677482  PMID: 25902482

Summary

Mutations in MECP2, encoding the epigenetic regulator methyl-CpG-binding protein 2, are the predominant cause of Rett syndrome, a disease characterized by both neurological symptoms and systemic abnormalities. Microglial dysfunction is thought to contribute to disease pathogenesis, and here we found microglia become activated and subsequently lost with disease progression in Mecp2-null mice. Mecp2 was found to be expressed in peripheral macrophage and monocyte populations, several of which also became depleted in Mecp2-null mice. RNA-seq revealed increased expression of glucocorticoid- and hypoxia-induced transcripts in Mecp2-null microglia and peritoneal macrophages. Furthermore, Mecp2 was found to regulate inflammatory gene transcription in response to TNF stimulation. Postnatal re-expression of Mecp2 using Cx3cr1creER increased the lifespan of otherwise Mecp2-null mice. These data suggest Mecp2 regulates microglia and macrophage responsiveness to environmental stimuli to promote homeostasis. Dysfunction of tissue-resident macrophages may contribute to the systemic pathologies observed in Rett syndrome.

Introduction

Rett syndrome, caused primarily by mutations in methyl-CpG binding protein 2 (MeCP2) (Amir et al., 1999), features prominent neurologic sequelae (Chahrour and Zoghbi, 2007); accordingly, efforts to understand the function of MeCP2 have been focused largely on its role in neurons (Chahrour and Zoghbi, 2007). Recent reports have found expression and roles for Mecp2 in astrocytes (Ballas et al., 2009; Lioy et al.; Yasui et al., 2013), oligodendrocytes (Nguyen et al., 2013), and microglia (Derecki et al., 2012; Maezawa and Jin, 2010). In addition, Mecp2 is expressed in many tissues (Shahbazian et al., 2002). Thus, mutations in MeCP2 likely affect multiple organ systems and cell types, which is indeed reflected in the complexity of symptoms associated with Rett syndrome (Chahrour and Zoghbi, 2007; Dunn and MacLeod, 2001). While neurological symptoms are prominent, most girls with Rett syndrome also suffer from somatic impairments, including stunted growth, osteopenia, scoliosis, and digestive difficulties (Chahrour and Zoghbi, 2007; Dunn and MacLeod, 2001).

Many tissue-resident macrophages, including microglia, originate during embryonic hematopoiesis, beginning in the yolk sac and moving to the fetal liver. These precursor cells disseminate throughout tissues during embryogenesis, engraft within nearly every organ system, and form self-renewing populations (Ginhoux et al., 2010; Hashimoto et al., 2013; Kierdorf et al., 2013; Schulz et al., 2012; Yona et al., 2013). Other populations of tissue-resident macrophages, such as intestinal lamina propria intestinal macrophages, are constantly replenished by circulating monocytes (Bain et al., 2013; Varol et al., 2009). The functional roles of tissue-resident macrophages vary greatly, and are dependent upon location and context (Davies et al., 2013). However, all tissue-resident macrophages appear to be unified by their role as provisioners of homeostatic maintenance (Davies et al., 2013). Further, monocyte-derived inflammatory non-resident macrophages are critical for effective response to infection and injury. In this context, these cells rely on a carefully balanced network of skewing paradigms, which direct macrophage function including the initiation and resolution of inflammation, clearance of debris and pathogens, and assistance in the healing process (Sica and Mantovani, 2012). Notably, mice lacking macrophage colony stimulating factor 1 receptor (CSF-1R) are deficient in all macrophages and are characterized by multiple organ failures and shortened lifespan (Dai et al., 2002), emphasizing the critical importance of macrophages in support of bodily tissues.

Our previous work demonstrated that engraftment of wild type monocytes into the brains of Mecp2-null mice (through bone marrow transplantation) extends lifespan by several months and improves neurologic and behavioral outcomes (Derecki et al., 2012). In addition, phagocytosis of apoptotic cells in vitro is impaired in Mecp2-null microglia. Although brain engraftment by monocytes with bone marrow transplant is crucial for significant lifespan extension in Mecp2-null mice (Derecki et al., 2012), we did not explore the possibility that Mecp2 might be important for the normal function of other mononuclear phagocytes.

Here we demonstrated that numerous populations of macrophages and monocytes expressed Mecp2, and that Mecp2-null mice become deficient in several macrophage populations, including microglia. We next showed that postnatal re-expression of Mecp2 under a Cx3cr1-inducible promoter resulted in a lifespan increase in otherwise Mecp2-null mice. In order to elucidate mechanisms behind the macrophage defects in the context of Mecp2-deficiency, we demonstrated by RNA-Seq that acutely isolated Mecp2-null microglia and peritoneal macrophages displayed changes in specific signaling pathways, suggesting that Mecp2 is an important regulator of microglia/macrophage gene expression. Further in vivo and in vitro validation studies confirmed that Mecp2 is important for proper transcriptional regulation of multiple gene expression programs in macrophages. Overall, these results demonstrated that Mecp2 is an important epigenetic regulator of macrophage response to stimuli and stressors.

Results

Microglia become activated and subsequently depleted with disease progression in Mecp2-null mice

Our previous data (Derecki et al., 2012) showing a role for microglia in disease pathogenesis of Mecp2-deficient mice led us to study in greater detail the role of Mecp2 in microglia and developmentally related peripheral tissue-resident macrophages. Wild type microglia were found to express Mecp2, as examined by intracellular flow cytometric labeling (Figure 1A) or by in situ immunofluorescence (Figure 1B). This is in line with previously reported results (Maezawa and Jin, 2010).

Figure 1. Microglia become activated and subsequently depleted with disease progression in Mecp2-null mice.

Figure 1

(A) Flow cytometry demonstrating Mecp2 expression in microglia from whole brain.

(B) Cryosections from Cx3cr1GFP/+ wild type mice demonstrating Mecp2 expression in microglia (scale bar, 20 µm). Images were cropped from larger images to allow for better visualization of Mecp2 localization within microglia.

(C) Representative stills from 2-photon live-imaging of late-phenotypic Cx3cr1GFP/+ wild type and Cx3cr1GFP/+ Mecp2-null microglia.

(D) Quantitative assessment of microglial soma size measured by two-photon intravital microscopy in pre- and late-phenotypic Cx3cr1GFP/+ wild type and Cx3cr1GFP/+ Mecp2-null mice (*, p < 0.05; **, p < 0.01; two-way ANOVA with Bonferroni post-test; n = 3 mice per group. Error bars represent SEM).

(E) Sholl profiles for pre- and late-phenotypic wild type and Mecp2-null microglia in hippocampus and neocortex showing intersections; (***, p<0.001; **, p<0.01; *, p<0.05; two-way ANOVA with Bonferroni post-test, n = 3 mice per group with 3 separate areas from slices from identical brain structures analyzed per each genotype. Data are presented as mean ±SEM).

(F,G) qRT-PCR of Tnf (F) and Tgfb1 (G) from pre- and late-phenotypic Mecp2-null mice and their age-matched wild type controls (*, p < 0.05; **, p < 0.01; two-way ANOVA with Bonferroni post-test, n = 3 mice for all groups except late-phenotypic wild type for which n = 5. Data are presented as mean ± SEM).

(H) Flow cytometric analysis demonstrating the percentage of microglia in whole brain preparations in Mecp2-null mice with increasing disease severity. Numbers show the percentage of Hoechst+ (nucleated) singlet CNS cells that are CD45loCD11b+ microglia.

(I) Quantification of microglia in pre- and late- phenotypic Mecp2-null mice as compared to age-matched wild type controls. Cells were gated on Hoechst+ (nucleated cells), Singlets, Size, and CD45lo/neg to exclude peripheral immune cells. (Two-way ANOVA with Bonferroni post-test; pre-phenotypic, not significant. Late-phenotypic; *, p<0.05. Pre-phenotypic vs. late-phenotypic Mecp2-null; *, p < 0.05. Overall main effect wild type vs. Mecp2-null; **, p < 0.01. n = 7 pairs of wild type and Mecp2-null mice pooled from 3 independent experiments for pre-phenotypic groups and n = 6 pairs of wild type and Mecp2-null mice pooled from 4 independent experiments for late-phenotypic groups. Error bars represent SEM).

(J) Brain region-specific microglia percentages as measured by flow cytometry in late-phenotypic Mecp2-null mice and age-matched wild type controls (*, p < 0.05; **, p < 0.01; ***, p < 0.001; two-way ANOVA; n = 6 mice per group. Error bars represent SEM).

We next investigated how loss of Mecp2 affects microglia in vivo. Using a thinned-skull technique, we performed intravital two-photon imaging on pre- and late-phenotypic Mecp2-null and wild type mice. We observed that pre-phenotypic Mecp2-null microglia had significantly smaller somas (similar to Mecp2-null neurons and astrocytes), while late-phenotypic Mecp2-null microglia soma were larger in size as compared to wild type (Figure 1C and 1D; Movies S1 and S2), suggestive of microglia activation (Kozlowski and Weimer, 2012). In addition, in situ Sholl analysis demonstrated that while pre-phenotypic Mecp2-null microglia were not different from wild type, microglia from late-phenotypic mice displayed significantly reduced process complexity in three examined brain areas (hippocampus, neocortex and cerebellum; Figure 1E). Together, the findings of increased soma size and decreased process complexity suggested that Mecp2-null microglia became activated with disease progression. Indeed, qRT-PCR of acutely isolated Mecp2-null microglia from pre- and late-phenotypic mice showed increased Tnf mRNA encoding the pro-inflammatory cytokine tumor necrosis factor (TNF) (Figure 1F) while Tgfb1 transcription, required for microglia maintenance (Butovsky et al., 2014), was decreased in late-phenotypic microglia (Figure 1G).

We next examined Mecp2-null microglia by flow cytometry, which revealed a progressive loss of microglia in Mecp2-null mice from pre- to late-phenotypic stage (Figure 1H and 1I). Loss of microglia was found throughout the brain (Figure 1J). The loss was also observed in brains of late-phenotypic Mecp2-null mice by immunohistochemistry (Figure S1A and S1B). Further, immunohistochemical staining for Iba1, a microglial marker, and for cleaved caspase 3 (CC3), a marker of apoptotic cells, revealed sporadic CC3+ microglia in late-phenotypic Mecp2-null brains (Figure S1C). In sum, these data suggest that in the context of Mecp2-deficiency, microglia become activated and are lost with disease progression.

Meningeal macrophages are lost with disease progression in Mecp2-null mice

When analyzing microglia by intravital two-photon microscopy, we also observed significant morphologic disruption of Cx3cr1GFP/+ meningeal macrophages in vivo in late-phenotypic Mecp2-null mice suggestive of reactive phenotype (Figure 2A). To assess meningeal macrophages in further detail, we performed immunofluorescent labeling of meninges from pre-, mid-, and late-phenotypic Mecp2-null mice using antibodies against CD163 and F4/80. A progressive loss of macrophages at the late-phenotypic state was evident in Mecp2-null mice (Figure 2B and 2C).

Figure 2. Meningeal macrophages are lost with disease progression in Mecp2-null mice.

Figure 2

(A) Representative stills from intravital two-photon microscopy of phenotypic Mecp2-null meningeal macrophages demonstrating abnormal/activated morphology.

(B) Representative images of wild type, mid and late-phenotypic Mecp2-null meningeal macrophages. Upper panels, scale bar = 200µm. Lower panels, scale bar = 100µm.

(C) Quantification of total meningeal macrophages in late-phenotypic Mecp2-null mice as compared to wild type, pre- and mid-phenotypic Mecp2-null (One-way ANOVA with Bonferroni post-test; **, p < 0.01. Error bars represent SEM).

(D) Quantification of F4/80+CD163+ perivascular meningeal macrophages in late-phenotypic Mecp2-null mice as compared to wild type, pre and mid-phenotypic Mecp2-null (One-way ANOVA with Bonferroni post-test; *, p < 0.01; **, p < 0.01. Error bars represent SEM).

(E) Quantification of F4/80+CD163non-perivascular meningeal macrophages in Mecp2-null mice as compared to wild type (One-way ANOVA with Bonferroni post-test. Error bars represent SEM).

Perivascular macrophages in the meninges are F4/80+CD163+, while a separate meningeal macrophage population is F4/80+CD163 (Davies et al., 2013). When we analyzed these populations separately, we found that perivascular macrophages (F4/80+CD163+) were progressively lost in Mecp2-null mice (Figure 2D), while non-perivascular meningeal macrophages (F4/80+CD163) were not significantly depleted (Figure 2E).

Peripheral monocytes and macrophages express Mecp2, and some are lost in Mecp2-null mice

Given the phenotype of meningeal macrophages and microglia, we decided to expand our analysis to additional populations of peripheral macrophages. Many tissue-resident macrophages, including microglia, originate from similar progenitor pools during embryogenesis (Ginhoux et al., 2010; Hashimoto et al., 2013; Kierdorf et al., 2013; Schulz et al., 2012; Yona et al., 2013), and might therefore share pathologies in the context of Mecp2-deficiency. We found that all tested tissue-resident macrophages expressed Mecp2 (Figure 3A and 3B). In addition, Ly6clo monocytes, which represent a longer-lived resident population in the blood (Yona et al., 2013) also expressed Mecp2 (Figure 3B). In contrast, Ly6chiCCR2+ monocytes and neutrophils expressed low or undetectable amounts of Mecp2 (Figure 3C).

Figure 3. Peripheral monocytes and macrophages express Mecp2, and some are lost in Mecp2-null mice.

Figure 3

(A) Example gating strategy for Mecp2 expression; shown are red pulp macrophages from spleen.

(B) Mecp2 expression in macrophage and monocyte populations as measured by intracellular flow cytometric staining in wild type and Mecp2-null mice. Gating: Bone marrow (BM)-resident macrophages- Size,CD45+,Singlets,Ly6c,F4/80+,CD11blo,CD3 ,SSClo; Splenic red pulp macrophages- CD45+,Singlets,F4/80+,B220,Size,SSClo,Ly6g ,Ly6c; Peritoneal resident macrophages- Size,Singlets,CD45+,CD11b+,F480hi; Intestinal macrophages- Singlets,viability,CD45+,CD11b+,CD64+; Splenic Ly6clo monocytes, CD45+,Singlets, CD115+,SSClo,Ly6clo.

(C) Flow cytometric Mecp2 staining in inflammatory monocytes (Ly6chiCCR2+) and neutrophils (Ly6ghiCD11b+). Gating: Splenic Ly6chiCCR2+ monocytes-CD45+,Singlets,CD115+,SSClo,Ly6chi; Neutrophils- Singlets,CD45+,CD11b+,Ly6g+.

(D, E) Flow cytometric analysis of resident intestinal macrophages in Mecp2-null mice as compared to wild type control. (D) Representative flow cytometry plots showing the percentage of CD64+F4/80+ out of all CD45+ intestinal cells in pre- and late-phenotypic Mecp2-null mice as compared to age-matched wild type controls. (E) Quantification of CD64+CD11b+ intestinal macrophages as measured by both percentage of total live intestinal cells (Two-way ANOVA with Bonferroni post-test; **, p < 0.01; ***, p < 0.001) and absolute cell counts per animal (Two-way ANOVA with Bonferroni post-test; **, p < 0.01; ***, p < 0.001). Data is representative of two independent experiments for phenotypic mice. Data are presented as mean ±SEM.

(F) Flow cytometry plots of Ly6chiCCR2+ and Ly6clo blood monocytes in pre- and late-phenotypic Mecp2-null mice as compared to age-matched wild type controls. Numbers represent percentage of cells out of Singlets, Live, CD45+CD11b+Ly6gCD115+SSClo monocytes.

(G) Quantification of numbers of circulating Ly6chiCCR2+ and Ly6clo monocytes (*, p<0.05; **, p<0.01; Two-way ANOVA with Bonferroni post-test; n = 6–8 mice per group. Error bars represent SEM).

(H) Representative plots of CD11b+CD115+ total monocytes from blood of wild type and Mecp2-null mice on day 5 post clodronate liposome injection.

(I) Monocyte count from peripheral blood of Mecp2-null and wild type controls on day 5 post clodronate liposome injection (unpaired two-tailed Student’s t-test, not significant. Error bars represent SEM).

(J) Representative flow cytometry plots displaying differentiation of Ly6chiCCR2+ monocytes to Ly6clo monocytes and quantification of %Ly6cloCCR2 resident monocytes on day 5 post clodronate liposome injection; representative of two independent experiments. (***, p<0.001, unpaired two-tailed Student’s t-test. Error bars represent SEM).

(K) Same as (J), except only DiI+ monocytes are shown (cells labeled on day 2 post clodronate injection via DiI liposome injection); representative of two independent experiments. ***, p<0.001 (unpaired two-tailed Student’s t-test. Error bars represent SEM).

As expected, based on the microglia and meningeal macrophage results described above, we found reductions of other peripheral macrophage populations in Mecp2-null mice. Unlike microglia, CD64+F4/80+CD11b+ macrophages from the small intestine were reduced in both pre- and late-phenotypic Mecp2-null mice (Figure 3D and 3E). Circulating Ly6clo monocytes were also reduced in number in both pre- and late-phenotypic Mecp2-null mice (Figure 3F and 3G).

Since both CD64+F4/80+CD11b+ intestinal macrophages and Ly6clo monocytes share their derivation from Ly6chi monocytes (Bain et al., 2013; Varol et al., 2009; Yona et al., 2013), it is possible that the reductions seen in these populations even in pre-phenotypic Mecp2-null mice may reflect their common origin. To this end, we tested whether Ly6chi monocytes from bone marrow were impaired in their ability to differentiate and/or proliferate as macrophages in response to MCSF in vitro. We found that Mecp2-null Ly6chi monocytes differentiated into macrophages with similar kinetics to wild type and produced similar numbers of macrophages per monocyte, making it an unlikely possibility that Mecp2 is directly necessary for Ly6chi monocyte differentiation or macrophage proliferation in the absence of other factors (Figure S2).

Although Mecp2 did not affect differentiation or proliferation in vitro, we hypothesized that Mecp2 might play a role in monocyte/macrophage responses within the context of the full disease caused by whole-animal Mecp2-deficiency. To test this possibility, we depleted monocytes and macrophages using IV clodronate liposomes in wild type and Mecp2-null littermates (mid-phenotypic, ~6 weeks to allow for immune system maturation but prior to the peak of disease), and measured the repopulation of resident monocytes. DiI liposomes were injected IV two days after clodronate liposome injection, similar to published protocols (Sunderkotter et al., 2004). Ly6chi monocytes released from the bone marrow become DiI labeled and can be tracked in their differentiation to Ly6clo monocytes. On day 5 post-clodronate injection (day 3 post DiI), wild type and Mecp2-null mice had, as expected, begun to reconstitute their circulating monocyte populations, with a non-significant trend towards fewer total monocytes (CD115+CD11b+) in Mecp2-null mice (Figure 3H and 3I). However, when total monocytes were examined, Mecp2-null mice had significantly fewer resident Ly6clo monocytes as compared to wild type (Figure 3J). In addition, when only DiI+ monocytes were examined (representing only the circulating monocytes present on day 2 post-clodronate injection), DiI+ monocytes in wild type mice had almost completely differentiated into Ly6clo resident monocytes, while Mecp2-null mice displayed a deficit in Ly6clo monocyte differentiation (Figure 3K). The fact that some populations were deficient in the pre-phenotypic state (resident monocytes and intestinal macrophages), but others were lost progressively (microglia and meningeal perivascular macrophages) led us to hypothesize that Mecp2 is likely playing a complex role in macrophage biology which is not limited to macrophage survival and/or death. Of note, we did not observe any difference in CD163F4/80+ meningeal macrophages (Figure 2E) or splenic red pulp macrophages (data not shown), which also express Mecp2 (Figure 3A and 3B), further suggesting that the role of Mecp2 in macrophages is complex or upstream of cell loss and/or death, since not all macrophage populations were equally affected by Mecp2-deficiency. In addition, our data regarding microglia suggested inflammatory activation (Figure 1C–G), implicating Mecp2-deficiency in processes beyond simple loss of microglia/macrophages. Overall, the data suggested a complex role for Mecp2 in macrophages, consistent with its previously described role in other cell types as an epigenetic regulator, affecting a multitude of genes (Guy et al., 2011).

Postnatal expression of Mecp2 via Cx3cr1creER in otherwise Mecp2-deficient mice increases lifespan

Previously we showed that transplantation of Mecp2-null mice with wild type bone marrow increases lifespan, and that engraftment of microglia-like cells into the brain is important for this effect (Derecki et al., 2012). More recently Cx3cr1creER mice have become available (Goldmann et al., 2013; Yona et al., 2013), and microglia are among a subset of macrophages with high expression of CX3CR1 during adulthood (Jung et al., 2000). Thus the Cx3cr1creER mouse can be used to efficiently target microglia, in addition to other CX3CR1-expressing monocytes and macrophages. Therefore, we crossed Cx3cr1creER mice with Mecp2Lox-stop mice and their offspring (Cx3cr1creER/+Mecp2Lox-stop/y) were treated with tamoxifen (~9 weeks of age), when symptoms just started to appear. In line with our previous finding with bone marrow transplantation (Derecki et al., 2012), the lifespan of tamoxifen-treated Cx3cr1creER/+Mecp2Lox-stop/y mice was significantly extended (Figure 4A) and weight loss was reversed as compared to oil-treated controls (Figure 4B), supporting the importance of microglia and macrophages in the arrest of pathology. In order to test for specificity of Mecp2 expression after tamoxifen treatment, we placed Cx3cr1creER/+Mecp2Lox-stop/y mice on a tamoxifen diet for 3 months to maximize expression in any cells that would have the potential to recombine. As expected, we found no significant expression of Mecp2 in T or B cells, and partial re-expression in monocytes (Figure 4C), as previously reported (Yona et al., 2013). In spleen, we found a small percentage of Mecp2-expressing red pulp macrophages (~20%) (Figure 4D), consistent with the fact that red pulp macrophages do not express high amounts of CX3CR1. However, CD64+F4/80+ intestinal macrophages and microglia, in which CX3CR1 is highly expressed, had nearly 100% Mecp2 recombination (Figure 4E and 4F). Non-microglia cells in the CNS displayed no Mecp2 recombination (Figure 4G). Together, these results support that Mecp2-deficiency in microglia/macrophages contributes to pathology, and that restoring Mecp2-mediated regulation of transcriptional responses has the potential to mediate benefits in the context of whole-body Mecp2-deficiency.

Figure 4. Postnatal expression of Mecp2 viaCx3cr1creER in otherwise Mecp2-deficient mice increases lifespan.

Figure 4

(A) Cx3cr1creER/+Mecp2Lox-stop/y mice after postnatal tamoxifen or oil control treatment in phenotypic mice (**, p<0.01; log-rank Mantel-Cox test; tamoxifen treated n = 8, oil treated n = 12).

(B) Weight change after postnatal tamoxifen or oil control treatment in phenotypic Cx3cr1creER/+Mecp2Lox-stop/y mice (**, p < 0.01; ***, p<0.001. Two-way ANOVA with Bonferroni post-test; n = 5 oil and n = 3 tamoxifen treated Cx3cr1creER/+Mecp2Lox-stop/y. n = 7 Cx3cr1creER/+Mecp2+/y tamoxifen treated. Asterisks over Cx3cr1creER/+Mecp2Lox-stop/y oil-treated indicate comparisons to Cx3cr1creER/+Mecp2Lox-stop/y tamoxifen-treated. Asterisks over Cx3cr1creER/+Mecp2Lox-stop/y tamoxifen-treated indicate comparisons to Cx3cr1creER/+Mecp2+/y. Data are presented as mean ± SEM).

(C-G) Analysis of Mecp2 re-expression in tamoxifen treated mice. Mice were fed tamoxifen food for 3 months to maximize possible recombination and analyzed by flow cytometry. Flow cytometry plots displaying Mecp2 expression in Cx3cr1creER/+Mecp2Lox-stop/y mice with or without tamoxifen treatment in (C) circulating monocytes, B, and T cells; (D) red pulp macrophages; (E) intestinal macrophages; (F) microglia and (G) total non-microglia nucleated cells in the CNS.

Mecp2 regulates glucocorticoid and hypoxia responses in microglia and peritoneal macrophages

In order to define the functional role of Mecp2 in macrophages we examined the global gene expression profile in microglia and peritoneal macrophages derived from Mecp2-null mice. We detected increased expression of glucocorticoid induced transcriptional signature genes in Mecp2-null cells when compared to their wild type counterparts, suggesting that Mecp2 functions as a repressor of this pathway (Figure 5A–D and Tables S1-S3). Among the dysregulated genes in Mecp2-null microglia and peritoneal macrophages, Fkbp5, a canonical glucocorticoid target gene, was strongly upregulated (Figure 5A and 5C). A number of studies have demonstrated that Mecp2 directly represses the Fkbp5 gene (Nuber et al., 2005; Urdinguio et al., 2008). Using chromatin immunoprecipitation analysis we demonstrated Mecp2 binding to the Fkbp5 gene promoter in bone marrow-derived macrophages (BMDM) (Figure 5E). Furthermore, Mecp2 deletion resulted in increased amounts of histone H4 acetylation at cis-regulatory regions of Fkbp5 gene under basal conditions (Figure 5F). These results suggest that Mecp2 restrains Fkbp5 gene expression through epigenetic mechanisms. ChIP analysis demonstrated the binding of nuclear receptor co-repressor 2 (Ncor2) and histone deacetylase 3 (Hdac3) to the promoter region at the Fkbp5 gene (Figure S3). These results are consistent with the well-established role of Mecp2 in the recruitment of the Ncor2 and Hdac3 complex to target genes (Ebert et al., 2013; Lyst et al., 2013). We next examined the Fkbp5 gene expression profile in dexamethasone-treated wild type and Mecp2-null macrophages. Our results revealed that Mecp2 controls the sensitivity of the Fkbp5 gene to glucocorticoid stimulation. Mecp2 deletion resulted in the upregulation of Fkbp5 gene expression under dexamethasone stimulation at a low dose normally incapable of triggering Fkbp5 gene expression (Figure 5G).

Figure 5. Mecp2 regulates glucocorticoid and hypoxia responses in microglia and peritoneal macrophages.

Figure 5

(A) Scatter plot comparing global gene expression profiles between wild type and Mecp2-null microglia. The black lines indicate a 2-fold cut-off for the difference in gene expression levels. Data represent the average of 6 wild type and 3 Mecp2-null samples, with each sample representing 3 pooled mice (thus, 18 mice and 9 mice respectively). mRNA expression is shown on a log2 scale.

(B) Gene set enrichment analysis (GSEA) reveals the over-representation of glucocorticoid transcription signature genes in Mecp2-null microglia. The middle part of the plot shows the distribution of the genes in the glucocorticoid transcription signature gene set (‘Hits’) against the ranked list of genes. Data represent the average of 6 wild type and 3 Mecp2-null samples.

(C) Scatter plot comparing global gene expression profiles between wild type and Mecp2-null peritoneal macrophages as in (A). Data represent the average of 6 pooled wild type and 6 pooled Mecp2-null mice.

(D) Global gene expression in wild type and Mecp2-null peritoneal macrophages was analyzed as in (B). Data represent the average of 6 pooled wild type and 6 pooled Mecp2-null mice.

(E) ChIP of Mecp2 from unstimulated wild type macrophages showing binding of Mecp2 to the promoter region of the Fkbp5 gene. Data were normalized to IgY (negative control). Data represent the average of three independent experiments. *** p < 0.001 and ** p < 0.01, (unpaired two-tailed Student’s t-test. Data are presented as mean ±SEM).

(F) ChIP analysis of histone H4 acetylation at the Fkbp5 gene promoter in wild type and Mecp2-null macrophages. Data represent the average of three independent experiments (*** p < 0.001 and ** p < 0.01; unpaired two-tailed Student’s t-test. Data are presented as mean ± SEM).

(G) Dexamethasone-stimulation of wild type and Mecp2-null macrophages was associated with a significant increase in Fkbp5 mRNA levels. Dexamethasone induction of Fkbp5 mRNA was significantly increased in Mecp2-null macrophages. Data represent the average of three independent experiments (*** p < 0.001 and ** p < 0.01; unpaired two-tailed Student’s t-test. Data are presented as mean ± SEM).

(H) Scatter plot comparing global gene expression profiles between wild type and Mecp2-null microglia. The black lines indicate a 2-fold cut-off for the difference in gene expression levels. Data represent the average of 6 wild type and 3 Mecp2-null samples, with each sample representing 3 pooled mice (18 and 9 mice respectively). mRNA expression levels are on a log2 scale.

(I) Gene-set enrichment analysis (GSEA) reveals the over-representation of hypoxia signature genes in unstimulated Mecp2-null microglia.

(J) Wild type and Mecp2-null macrophages were grown in hypoxia or normoxia for 24 hrs. mRNA levels of Hif3a Ddit4, and Cyr61 were measured using qRT-PCR. Results are representative of three independent experiments (average of three values  ±  SEM; *** p < 0.001 by unpaired two-tailed Student’s t-test).

We noticed that the glucocorticoid-induced gene set contains a number of hypoxia-inducible genes (Table S3). Furthermore, our gene set enrichment analysis demonstrated significantly increased expression of a subset of hypoxia-inducible genes in Mecp2-null microglia (Figure 5H and 5I). To validate the cell-intrinsic role for Mecp2 in the negative regulation of these hypoxia-inducible genes, we cultured BMDM under either normoxia or hypoxia conditions (1% O2) and examined their mRNA using quantitative PCR analysis. We validated increased expression of three canonical hypoxia-inducible genes, Hif3a, Ddit4, and Cyr61 in Mecp2-null macrophages cultured under hypoxia conditions when compared to their wild type counterparts (Figure 5J), confirming a role for Mecp2 in regulation of at least a subset of hypoxia-induced gene transcripts.

Mecp2 restrains inflammatory responses in macrophages

Our RNA-Seq analysis revealed increased expression of Tnf induced transcriptional signature genes in Mecp2-null microglia cells when compared to their wild type counterparts (Table S2). These results indicate that Mecp2-deficiency leads to dysregulation of inflammatory responses in microglia and macrophages. To validate this finding, we examined the role of Mecp2 in the regulation of TNF-induced inflammatory responses in macrophages. We observed increased expression of Il6, Tnf, Cxcl2, Cxcl3, and Csf3 genes in TNF-stimulated Mecp2-null BMDM when compared to wild type counterparts (Figure 6A). In order to corroborate these findings in vivo, we examined the inflammatory response of resident peritoneal macrophages. Mice were injected intraperitoneally with TNF, allowed to respond for 6 hours, and then peritoneal cells were collected by lavage. Cells from peritoneal lavage were positively selected for F4/80+ macrophages via AutoMACS. Peritoneal macrophages from Mecp2-null mice injected with TNF displayed an altered transcriptional response as compared to wild type (Figure 6B), including both over- and under-expression of multiple TNF response genes. No differences in baseline expression were evident in peritoneal macrophages from mice after saline treatment (Figure S4). Targets observed in vitro with TNF stimulated BMDM were also over expressed in peritoneal macrophages stimulated with TNF in vivo, suggesting that Mecp2 has consistent transcriptional roles across macrophage populations (Figure 6A and 6B).

Figure 6. Mecp2 restrains inflammatory responses in macrophages.

Figure 6

(A) Wild type and Mecp2-null macrophages were treated for 6 hr with TNF and subjected to quantitative real time PCR (qRT-PCR) for Tnf Il6 Cxcl2 Cxcl3, and Csf3. Data are representative of three experiments (average of three values ± SEM; ***, p < 0.001 and ** p < 0.01; Two-way ANOVA with Bonferroni post-test).

(B) Mecp2-null or age-matched wild type mice were injected with intraperitoneal TNF and allowed to respond for 6 hr. Resident peritoneal macrophages were collected by lavage and subsequent AutoMACS sort for F4/80+ cells. RNA was collected and qRT-PCR performed for the indicated genes (*, p < 0.05; Two-way ANOVA with Bonferroni post-test. Interaction for Genotype and Gene; *, p = 0.01. N = 3 wild type and 4 Mecp2-null. Data are presented as mean ± SEM).

(C) Granulocyte colony-stimulating factor (GCSF) ELISA of serum from late-phenotypic Mecp2-null mice and wild type controls (*, p < 0.05; Mann-Whitney two-tailed; n = 9 per group. Data are presented as mean ± SEM).

(D) Representative flow cytometry plots of Mecp2-null and wild type mice treated with anti-GCSF neutralizing or isotype antibodies showing percentage of neutrophils out of all CD45+ circulating blood cells. Plots are representative of two independent experiments performed with n = 2 mice for all groups, analyzed 1–2 weeks post start of injections.

(E) Survival of Mecp2-null mice treated with either anti-GCSF neutralizing or isotype antibodies (*, p < 0.05; log-rank Mantel-Cox test; n = 11 per group).

Csf3, the gene encoding granulocyte-colony stimulating factor (GCSF), was over expressed in TNF-stimulated Mecp2-null macrophages both in vitro and in vivo (Figure 6A and 6B). Late-phenotypic Mecp2-null mice without any manipulation also displayed increased GCSF protein in serum (Figure 6C). Since a well-established effect of GCSF is to stimulate neutrophil production (Bendall and Bradstock, 2014), we examined neutrophil numbers in Mecp2-null mice. Indeed, we found that Mecp2-null mice develop severe neutrophilia (Figure S5A and S5B). In addition, GCSF is known to drive the egress of hematopoietic stem cells (HSC) from the bone marrow (Bendall and Bradstock, 2014) and as expected, late-phenotypic Mecp2-null mice also became progressively deficient in bone marrow HSC with disease progression (Figure S5C and S5D). In order to test whether or not neutrophilia and HSC loss play a role in the disease, we treated Mecp2-null mice with a neutralizing anti-GCSF antibody beginning at age 6–7 weeks (a mid-phenotypic time-point). Flow cytometric analysis revealed rescue of neutrophilia (Figure 6D) and prevention of HSC loss (Figure S5E). The treatment also moderately increased the lifespan of Mecp2-null mice (Figure 6E).

Together, these findings implicate Mecp2 in control of the macrophage inflammatory response, which may have downstream implications for complex disease processes in the context of Mecp2-deficiency.

Discussion

In this work we have demonstrated that Mecp2 is widely expressed across macrophage populations, and that Mecp2-deficiency leads to transcriptional impairment and/or loss of macrophages in multiple tissues. Postnatal genetic rescue of several tissue- resident macrophage and monocyte populations via Cx3cr1creER mediated expression of Mecp2 resulted in increased lifespan. We have further provided evidence that Mecp2 is required for macrophage responses to multiple stimuli through both RNA-Seq of acutely isolated Mecp2-null microglia and peritoneal macrophages, and both in vitro and in vivo validation of pathways identified through RNA-Seq. Together, these findings implicate macrophages, and potentially monocytes, as previously unrecognized players in Rett syndrome pathology. Our results also suggest that Mecp2 is an important regulator of macrophage response to stimuli/stressors, and future work examining the mechanisms of transcriptional and epigenetic regulation of macrophage responses should take into account the role of Mecp2 in macrophage activation.

These findings support the notion that both malfunction and loss of macrophages and resident monocytes may be a contributing factor in Rett syndrome pathologies occurring across multiple organ systems. Our finding that Mecp2-null macrophages display impaired response to multiple stimuli–including glucocorticoids, hypoxia, and inflammation–may be of particular importance in the context of Mecp2-deficient animals, as the level of general organ dysfunction is high compared to wild type mice; therefore, ongoing dysfunction of other cell types, such as neurons, may increase the cellular stress/activation upon Mecp2-null microglia and macrophages and thereby exacerbate their loss and/or further pathology induced by maladaptive responses to stimuli by Mecp2-null macrophages. Such a positive feedback loop involving multiple cell types and tissues could help explain the progressive development of symptoms in Mecp2-null mice, which ultimately lead to death. These results may also explain why cell-specific deletion of Mecp2 in microglia cells did not result in significant symptoms of Rett syndrome (unpublished observations); Mecp2-null microglia and macrophages represent amplifiers of pathology, driven primarily by neurons, and thus their replacement by wild type cells abrogates the otherwise vicious cycle and slows down the disease progression; however without the pathology driven by neurons (such as apneas, abnormal glucocorticoid response, etc.), Mecp2-null microglia cannot induce a Rett-like pathology.

It is well-recognized that girls suffering from Rett syndrome experience severe problems outside the CNS, such as gastrointestinal distention, defects of nutrient absorption, scoliosis, osteopenia, and general somatic growth deficits (Chahrour and Zoghbi, 2007; Dunn and MacLeod, 2001). Intestines contain a large number of immune cells, including a significant fraction of macrophages (Zigmond and Jung, 2013). Osteoclasts are key players in bone turnover and homeostasis (Davies et al., 2013). Thus, it is conceivable that pathology in both the gastrointestinal tract and the bones could be exacerbated by defects of tissue-resident macrophage function and/or loss of tissue-resident macrophages in these tissues. It has been suggested that macrophages may be one of the two largest sources of insulin-like growth factor 1 (IGF-1), which is a critical growth factor involved in growth and health of a multitude of tissues (Gow et al., 2010). In addition, IGF-1 treatment has been shown to increase the lifespan of Mecp2-null mice (Tropea et al., 2009) and recently initiated clinical trials are promising (Khwaja et al., 2014). It is therefore possible that functional defects and loss of tissue-resident macrophages in Mecp2-deficient mice, and possibly Rett syndrome, may contribute to overall pathology via deficiency of macrophage-derived IGF-1. Moreover, our RNA-seq data shows that Mecp2-null microglia express increased amounts of Igfbp3, a binding protein for IGF-1, which binds soluble IGF-1 and neutralizes its function.

In recent groundbreaking work examining deletion of Mecp2 in adult mice, phenotypic progression is similar in time-scale to that seen in mice null from birth (McGraw et al., 2011). This may support the hypothesis that accumulation of cellular stress in the absence of Mecp2 is progressively detrimental to cells necessary for tissue homeostasis, such as tissue-resident macrophages.

Beyond Rett syndrome, this work suggests that Mecp2 is an epigenetic regulator of macrophages. Given the diversity and plasticity of macrophages across organ systems, understanding the role of Mecp2 in each specific macrophage population may prove a difficult task. However, understanding the role of Mecp2 in macrophages, and the immune system as a whole, could lead to greater understanding of several diseases in addition to Rett syndrome, including MeCP2 duplication/triplication syndrome (Chahrour and Zoghbi, 2007), and systemic lupus erythematosus (Koelsch et al., 2013), which has been linked to abnormalities of MeCP2 in humans.

We found genetic dysregulation in response to multiple stimulations in Mecp2-null macrophages, which in vivo may act alone or in concert depending upon the exact conditions presented to the cell. For instance, many of the hypoxia-induced transcripts measured to be abnormal in Mecp2-null macrophages, were also found in the disrupted glucocorticoid pathways identified by RNA-Seq. Therefore, such transcripts might represent independent dysfunction in Mecp2-null macrophages in the context of hypoxia alone, or an additional complication of glucocorticoid-induced transcription depending on context. Further, the combination of glucocorticoid stimulation and hypoxia might result in complex transcriptional dysregulation.

Our validation studies of inflammatory-, hypoxia-, and glucocorticoid- signaling confirm a macrophage-intrinsic role for Mecp2 in proper execution of these transcriptional responses. We validated in vitro that stimulation of Mecp2-null macrophages demonstrates excessive and dysregulated inflammatory response and excessive response to low-dose glucocorticoids, which have been previously shown to contribute to pathology in mouse models of Mecp2-deficiency (Braun et al., 2012). Of particular note, we found that Mecp2-null mice develop an inflammatory activation of microglia with disease progression, and that resident peritoneal macrophages stimulated with TNF in vivo, or BMDM stimulated with TNF in vitro, have an abnormal transcriptional response which implicates Mecp2 as a key regulator of inflammatory gene programs in macrophages. Of note, TNF is a widely used cytokine with important functions in both the CNS and PNS in the context of normal, non-inflammatory function and development (Stellwagen and Malenka, 2006; Wheeler et al., 2014). Based on what we have demonstrated in macrophages, it is possible that TNF signaling in neurons is also impaired in the absence of Mecp2, potentially contributing to abnormal neuronal function and/or development in Rett syndrome. This possible cascade will be evaluated in future studies.

These results provide evidence that Mecp2 plays an important role in the epigenetic regulation of macrophage responses and implicate macrophages as therapeutic targets in Rett syndrome. Importantly, we found that three stimuli (glucocorticoids, hypoxia, and inflammation) were transcriptionally dysfunctional in the absence of Mecp2, associating Mecp2 as a widely used epigenetic regulator in macrophages. Given that Mecp2 regulates multiple response pathways in macrophages, it is important to note that the exact effects of Mecp2-deficiency in macrophages in the context of a severe whole-body disease such as Rett syndrome becomes extremely difficult to predict, especially when one considers the variation in location, context, and functions of macrophages throughout the body. Thus, future studies should consider Mecp2 as an important player in the transcriptional regulation of macrophage responses and endeavor to understand the role of Mecp2 in the many unique macrophage populations.

Experimental Procedures

Additional experimental procedures can be found in the supplemental materials.

Animals

Male and female C57Bl/6J, B6.129P2(C)-Mecp2tm1.1Bird/J, B6.129P2-Mecp2tm2Bird/J, and B6.129P–Cx3cr1tm1Litt/J mice were purchased from Jackson Laboratories and/or bred in house using stock obtained from Jackson Laboratories. Cx3cr1creER mice were kindly provided by S. Jung (Weizmann Institute of Science, Rehovot, Israel) and were maintained in our laboratory on C57Bl/6J background. All animals were housed in temperature and humidity controlled rooms, and maintained on a 12 h/12 h light/dark cycle (lights on at 7:00). All strains were kept in identical housing conditions. Mice were scored for pathology based on a 3-point scale across four categories: hind-limb-clasping, tremors, gait, and general appearance. For each category, 3 = wild type, 2 = mid-phenotypic, and 1 = late-phenotypic. Mice that scored in-between 3 and 2 were considered early/pre-phenotypic. Approximate ages for pre-phenotypic mice were 4–5 weeks, and for late-phenotypic 8–12 weeks; however, all experiments were performed and labeled based on actual phenotype of the mice. All procedures complied with regulations of the Institutional Animal Care and Use Committee at The University of Virginia.

Tamoxifen treatment

Tamoxifen (Sigma T5648) was solubilized in corn oil (Sigma) at 10 mg/ml. Mice were injected 3 times, subcutaneously, between the shoulder blades, at 48 h intervals at a dose of 100 mg/kg. For tamoxifen feeding, mice were placed on tamoxifen diet TD.130856 (Harlan Laboratories) for up to 3 months before analysis, while controls were left on normal mouse chow (Harlan Laboratories).

RNA-seq analysis

Total RNA was extracted using the RNeasy mini kit (Qiagen). RNA-Seq was performed by Hudson Alpha Genomic Services Laboratory. Statistical analysis and data postprocessing were performed with in-house developed functions in Matlab (Litvak et al., 2009; Litvak et al., 2012). For transcriptome analysis of wild type and Mecp2-null microglia and peritoneal macrophages, genes were selected for inclusion on the basis of filtering for minimum log2 expression intensity (>4).

Gene Set Enrichment Analysis

GSEA is an analytical tool for relating differentially regulated genes to transcriptional signatures and molecular pathways associated with known biological functions3. The statistical significance of the enrichment of known transcriptional signatures in a ranked list of genes was determined as described (Subramanian et al., 2005). To assess the phenotypic association with Mecp2 deficiency, we used the list of genes that was ranked according to differential gene expression in Mecp2-null and wild type microglia. We used 4,722 gene sets from the Molecular Signature Database C2 version 4.0 and 32 custom gene sets including hypoxia and glucocorticoid-stimulated gene sets (Table S1).

Quantitative chromatin immunoprecipitation (ChIP) analysis

For ChIP analysis formalin-fixed cells were sonicated and processed for immunoprecipitation essentially as described (Ning et al., 2011). In brief, 1.5 × 107 BMMs were cross-linked for 10 min in 1% paraformaldehyde, washed and lysed. Chromatin was sheared by sonication (5 × 60 s at 30% maximum potency) to fragments of approximately 150 bp. For anti-Mecp2 antibodies ChIP, the sheared chromatin was incubated with Mecp2 (ABE171) (Millipore), and then immunoprecipitated using anti-rabbit IgG Dynabeads (Invitrogen) pre-conjugated with anti-Chicken IgY antibodies (ab6877) (Abcam); washed and eluted. For acH4 ChIP, the sheared chromatin was incubated with anti-rabbit IgG Dynabeads (Invitrogen) pre-conjugated with antibodies acH4 (06–598) (Upstate) or Isotype control IgG1 (BD Pharmigen); washed and eluted. Eluted chromatin was reverse-cross-linked, and DNA was purified using phenol/chloroform/isoamyl extraction.

For quantitative ChIP, immunoprecipitated DNA samples were amplified with Fkbp5-promoter-specific primers (Forward: TGCACTGCCTATGCAAATGA and Reverse: AGCTTCCTCCATCCCTCTT) using TaqMan quantitative PCR analysis. PCR samples from IgY-ChIPs served as a negative control.

Accession numbers

The Gene Expression Omnibus (GEO) accession number for the RNA-Seq data reported in this paper is GSE66211. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66211

The Gene Expression Omnibus (GEO) accession number for the ChIP-Seq data reported in this paper is GSE66502. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66502

Supplementary Material

1
2
3
4
5
Download video file (1.6MB, mov)
6
Download video file (1.2MB, mov)

Acknowledgments

We thank Shirley Smith for editorial assistance and Dr. Alex Koeppel (Bioinformatics core, School of Medicine, University of Virginia) for his initial analysis of RNA-Seq data. We thank Dr. Arthur Mercurio and Bryan Pursell (Department of Molecular, Cell and Cancer Biology, UMass Medical School) for their help with hypoxia experiments. We thank the members of the Kipnis lab as well as the members of the Center for Brain Immunology and Glia (BIG) for their valuable comments during multiple discussions of this work. Noël C. Derecki was supported by Hartwell Foundation post-doctoral fellowship. James C. Cronk was supported by an award from the National Institute of Allergy and Infectious Diseases 1F30AI109984. This work was primarily supported by a grant from the National Institutes of Neurological Disorders and Stroke NS081026 (J. K), the Simons Foundation Autism Research Initiative (J. K.), and from the Rett Syndrome Research Trust (J. K.).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Author contributions

J.C. Cronk and N.C. Derecki designed the experiments, performed the experiments, analyzed the data, and wrote the manuscript.

E. Ji assisted with flow cytometry and immunohistochemistry experiments.

Y. Xu analyzed RNA-Seq data and performed in vitro experiments.

A. Lampano performed in vitro experiments.

I. Smirnov participated in all experiments with experimental animals.

W. Baker assisted with maintenance and genotyping of experimental animals.

G.T. Norris performed the microglia Sholl analysis.

I. Marin assisted with intestinal preparations.

N. Coddington assisted with in vitro experiments.

A. Aderem provided ChIP-Seq data.

Y. Wolf and S. Jung generated and provided the transgenic mice (Cx3cr1creER).

A. Klibanov provided liposomes.

T. Harris assisted with the intravital experiments.

V. Litvak designed the experiments, analyzed data, and wrote the manuscript.

J. Kipnis conceived and led the project, designed the experiments and wrote the manuscript.

References

  1. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature genetics. 1999;23:185–188. doi: 10.1038/13810. [DOI] [PubMed] [Google Scholar]
  2. Bain CC, Scott CL, Uronen-Hansson H, Gudjonsson S, Jansson O, Grip O, Guilliams M, Malissen B, Agace WW, Mowat AM. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal immunology. 2013;6:498–510. doi: 10.1038/mi.2012.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ballas N, Lioy DT, Grunseich C, Mandel G. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nature neuroscience. 2009;12:311–317. doi: 10.1038/nn.2275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bendall LJ, Bradstock KF. G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine & growth factor reviews. 2014;25:355–367. doi: 10.1016/j.cytogfr.2014.07.011. [DOI] [PubMed] [Google Scholar]
  5. Braun S, Kottwitz D, Nuber UA. Pharmacological interference with the glucocorticoid system influences symptoms and lifespan in a mouse model of Rett syndrome. Human molecular genetics. 2012;21:1673–1680. doi: 10.1093/hmg/ddr602. [DOI] [PubMed] [Google Scholar]
  6. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nature neuroscience. 2014;17:131–143. doi: 10.1038/nn.3599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron. 2007;56:422–437. doi: 10.1016/j.neuron.2007.10.001. [DOI] [PubMed] [Google Scholar]
  8. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V, Stanley ER. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 2002;99:111–120. doi: 10.1182/blood.v99.1.111. [DOI] [PubMed] [Google Scholar]
  9. Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nature immunology. 2013;14:986–995. doi: 10.1038/ni.2705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Derecki NC, Cronk JC, Lu Z, Xu E, Abbott SB, Guyenet PG, Kipnis J. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature. 2012;484:105–109. doi: 10.1038/nature10907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dunn HG, MacLeod PM. Rett syndrome: review of biological abnormalities. Can J Neurol Sci. 2001;28:16–29. doi: 10.1017/s0317167100052513. [DOI] [PubMed] [Google Scholar]
  12. Ebert DH, Gabel HW, Robinson ND, Kastan NR, Hu LS, Cohen S, Navarro AJ, Lyst MJ, Ekiert R, Bird AP, Greenberg ME. Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR. Nature. 2013;499:341–345. doi: 10.1038/nature12348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Faustino JV, Wang X, Johnson CE, Klibanov A, Derugin N, Wendland MF, Vexler ZS. Microglial cells contribute to endogenous brain defenses after acute neonatal focal stroke. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2011;31:12992–13001. doi: 10.1523/JNEUROSCI.2102-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841–845. doi: 10.1126/science.1194637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Goldmann T, Wieghofer P, Muller PF, Wolf Y, Varol D, Yona S, Brendecke SM, Kierdorf K, Staszewski O, Datta M, et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nature neuroscience. 2013;16:1618–1626. doi: 10.1038/nn.3531. [DOI] [PubMed] [Google Scholar]
  16. Gow DJ, Sester DP, Hume DA. CSF-1, IGF-1, and the control of postnatal growth and development. J Leukoc Biol. 2010;88:475–481. doi: 10.1189/jlb.0310158. [DOI] [PubMed] [Google Scholar]
  17. Guy J, Cheval H, Selfridge J, Bird A. The role of MeCP2 in the brain. Annual review of cell and developmental biology. 2011;27:631–652. doi: 10.1146/annurev-cellbio-092910-154121. [DOI] [PubMed] [Google Scholar]
  18. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, Becker CD, See P, Price J, Lucas D, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013;38:792–804. doi: 10.1016/j.immuni.2013.04.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20:4106–4114. doi: 10.1128/mcb.20.11.4106-4114.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Khwaja OS, Ho E, Barnes KV, O’Leary HM, Pereira LM, Finkelstein Y, Nelson CA, 3rd, Vogel-Farley V, DeGregorio G, Holm IA, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:4596–4601. doi: 10.1073/pnas.1311141111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, Wieghofer P, Heinrich A, Riemke P, Holscher C, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci. 2013;16:273–280. doi: 10.1038/nn.3318. [DOI] [PubMed] [Google Scholar]
  22. Koelsch KA, Webb R, Jeffries M, Dozmorov MG, Frank MB, Guthridge JM, James JA, Wren JD, Sawalha AH. Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse. Journal of autoimmunity. 2013;41:168–174. doi: 10.1016/j.jaut.2012.12.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kozlowski C, Weimer RM. An automated method to quantify microglia morphology and application to monitor activation state longitudinally in vivo. PloS one. 2012;7:e31814. doi: 10.1371/journal.pone.0031814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lioy DT, Garg SK, Monaghan CE, Raber J, Foust KD, Kaspar BK, Hirrlinger PG, Kirchhoff F, Bissonnette JM, Ballas N, Mandel G. A role for glia in the progression of Rett’s syndrome. Nature. 475:497–500. doi: 10.1038/nature10214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Litvak V, Ramsey SA, Rust AG, Zak DE, Kennedy KA, Lampano AE, Nykter M, Shmulevich I, Aderem A. Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nature immunology. 2009;10:437–443. doi: 10.1038/ni.1721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Litvak V, Ratushny AV, Lampano AE, Schmitz F, Huang AC, Raman A, Rust AG, Bergthaler A, Aitchison JD, Aderem A. A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses. Nature. 2012;490:421–425. doi: 10.1038/nature11428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lyst MJ, Ekiert R, Ebert DH, Merusi C, Nowak J, Selfridge J, Guy J, Kastan NR, Robinson ND, de Lima Alves F, et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nature neuroscience. 2013;16:898–902. doi: 10.1038/nn.3434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Maezawa I, Jin LW. Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J Neurosci. 30:5346–5356. doi: 10.1523/JNEUROSCI.5966-09.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Maezawa I, Jin LW. Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2010;30:5346–5356. doi: 10.1523/JNEUROSCI.5966-09.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. McGraw CM, Samaco RC, Zoghbi HY. Adult neural function requires MeCP2. Science. 2011;333:186. doi: 10.1126/science.1206593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Nguyen MV, Felice CA, Du F, Covey MV, Robinson JK, Mandel G, Ballas N. Oligodendrocyte lineage cells contribute unique features to Rett syndrome neuropathology. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013;33:18764–18774. doi: 10.1523/JNEUROSCI.2657-13.2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Nicol JW, Helt GA, Blanchard SG, Jr, Raja A, Loraine AE. The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasets. Bioinformatics. 2009;25:2730–2731. doi: 10.1093/bioinformatics/btp472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and function. Genes and immunity. 2011;12:399–414. doi: 10.1038/gene.2011.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Nuber UA, Kriaucionis S, Roloff TC, Guy J, Selfridge J, Steinhoff C, Schulz R, Lipkowitz B, Ropers HH, Holmes MC, Bird A. Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. Hum Mol Genet. 2005;14:2247–2256. doi: 10.1093/hmg/ddi229. [DOI] [PubMed] [Google Scholar]
  35. Ramsey SA, Knijnenburg TA, Kennedy KA, Zak DE, Gilchrist M, Gold ES, Johnson CD, Lampano AE, Litvak V, Navarro G, et al. Genome-wide histone acetylation data improve prediction of mammalian transcription factor binding sites. Bioinformatics. 2010;26:2071–2075. doi: 10.1093/bioinformatics/btq405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Schneider A, Kuhn HG, Schabitz WR. A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system. Cell cycle. 2005;4:1753–1757. doi: 10.4161/cc.4.12.2213. [DOI] [PubMed] [Google Scholar]
  37. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, Prinz M, Wu B, Jacobsen SE, Pollard JW, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336:86–90. doi: 10.1126/science.1219179. [DOI] [PubMed] [Google Scholar]
  38. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Human molecular genetics. 2002;11:115–124. doi: 10.1093/hmg/11.2.115. [DOI] [PubMed] [Google Scholar]
  39. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. The Journal of clinical investigation. 2012;122:787–795. doi: 10.1172/JCI59643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. Nature. 2006;440:1054–1059. doi: 10.1038/nature04671. [DOI] [PubMed] [Google Scholar]
  41. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:15545–15550. doi: 10.1073/pnas.0506580102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, Leenen PJ. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. Journal of immunology. 2004;172:4410–4417. doi: 10.4049/jimmunol.172.7.4410. [DOI] [PubMed] [Google Scholar]
  43. Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, Flannery R, Jaenisch R, Sur M. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:2029–2034. doi: 10.1073/pnas.0812394106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Urdinguio RG, Lopez-Serra L, Lopez-Nieva P, Alaminos M, Diaz-Uriarte R, Fernandez AF, Esteller M. Mecp2-null mice provide new neuronal targets for Rett syndrome. PloS one. 2008;3:e3669. doi: 10.1371/journal.pone.0003669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Varol C, Vallon-Eberhard A, Elinav E, Aychek T, Shapira Y, Luche H, Fehling HJ, Hardt WD, Shakhar G, Jung S. Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity. 2009;31:502–512. doi: 10.1016/j.immuni.2009.06.025. [DOI] [PubMed] [Google Scholar]
  46. Wheeler MA, Heffner DL, Kim S, Espy SM, Spano AJ, Cleland CL, Deppmann CD. TNF-alpha/TNFR1 signaling is required for the development and function of primary nociceptors. Neuron. 2014;82:587–602. doi: 10.1016/j.neuron.2014.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Yasui DH, Xu H, Dunaway KW, Lasalle JM, Jin LW, Maezawa I. MeCP2 modulates gene expression pathways in astrocytes. Mol Autism. 2013;4:3. doi: 10.1186/2040-2392-4-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, Strauss-Ayali D, Viukov S, Guilliams M, Misharin A, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38:79–91. doi: 10.1016/j.immuni.2012.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Zigmond E, Jung S. Intestinal macrophages: well educated exceptions from the rule. Trends Immunol. 2013;34:162–168. doi: 10.1016/j.it.2013.02.001. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1
2
3
4
5
Download video file (1.6MB, mov)
6
Download video file (1.2MB, mov)

RESOURCES